Assessment of the Value of Nivolumab Plus Ipilimumab for Treating Microsatellite Instability-High/Mismatch Repair Deficiency Metastatic Colorectal Cancer: Indirect Treatment Comparison and Cost-Effectiveness Analysis.
INTRODUCTION Colorectal cancer (CRC) is the third most common cancer and has the second highest global economic burden of all cancers. Among metastatic CRC (mCRC) cases, 4-5% are microsatellite instability-high/mismatch repair deficiency (MSI-H/dMMR) for which, up until recently, pembrolizumab was the recommended first...